European urology

01 20 October 2026

DOI 10.1016/j.eururo.2026.09.030

In Response to “Five-Year Patient-reported Outcomes After SBRT for Prostate Cancer: A Benchmark for Radiotherapy, but How Far Across Modalities?” Pierre Blanchard, Chiara Sighinolfi, Mario Terlizzi, et al. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2026.07.023

Open DOI

Sian Cooper, Busola Adebusoye, Caroline M. Moore et al.

02 20 October 2026

DOI 10.1016/j.eururo.2026.10.001

Reply to Roberto Mario Scarpa’s Letter to the Editor: Sham or Active Control in MIST Trials? A False Methodological Dichotomy. re: Baboudjian M, Nunzio C, Elterman D, et al. What is the Standard Comparator of Minimally Invasive Surgical Therapies (MIST) for Benign Prostatic Obstruction? Medical Versus Surgical Treatment. Eur Urol. 2026 Aug;90(2):95-97.

Open DOI

Michael Baboudjian, Jean-Nicolas Cornu

03 16 October 2026

DOI 10.1016/j.eururo.2026.09.033

Re: Kari A. O. Tikkinen, Maura Marcucci, Alex L. E. Halme, et al. Safety and Efficacy of Tranexamic Acid in Urologic Surgery: Results from the International, Randomized, Placebo-controlled POISE-3 Trial. Eur Urol 2026;90:140–9

Open DOI

Kristoffer Mazanti Cold, Frederik Ferløv Thomsen, Jakob Stensballe et al.

04 15 October 2026

DOI 10.1016/j.eururo.2026.08.030

Re: Arie Parnham, Maarten Albersen, Benjamin Ayres, et al. European Association of Urology and American Society of Clinical Oncology Guidelines on Penile Cancer: A Summary of the 2026 Guidelines Update. Eur Urol 2026;90:60–71

Open DOI

Marco Bandini, Francesco Montorsi

05 12 October 2026

DOI 10.1016/j.eururo.2026.09.005

177Lu-Prostate-specific Membrane Antigen Prior to Stereotactic Ablative Radiotherapy in Oligorecurrent Prostate Cancer: Secondary and Exploratory End Point Results from the Randomized Phase 2 LUNAR Trial

Open DOI

Amar U. Kishan, Holly Wilhalme, Carol Felix et al.

06 9 October 2026

DOI 10.1016/j.eururo.2026.09.019

Reply to Dachun Jin, Chi-Fai Ng, and Peter Ka-Fung Chiu’s Letter to the Editor re: Bi-Ming He, Keqin Zhang, Zhien Zhou, et al. Cognitive Versus Software-based Fusion Targeted Biopsy for the Diagnosis of Clinically Significant Prostate Cancer: A Multicenter, Randomized, Noninferiority Trial (IMAGINATION). Eur Urol. In press. https://doi.org/10.1016/j.eururo.2026.06.020

Open DOI

Bi-Ming He, Hai-Feng Wang

07 9 October 2026

DOI 10.1016/j.eururo.2026.08.015

Reply to Sho Todo, Keiichiro Kitahama, and Kentaro Inamura's Letter to the Editor re: Wenxin Xu, Brian I. Rini, Laurence Albiges, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol. 2026 Apr 25:S0302-2838(26)02060-9

Open DOI

Wenxin Xu, Brian I. Rini, Laurence Albiges et al.

08 7 October 2026

DOI 10.1016/j.eururo.2026.09.014

Re: Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Bladder Cancer

Open DOI

Veronica Mollica, Matteo Rosellini, Matteo Santoni et al.

09 6 October 2026

DOI 10.1016/j.eururo.2026.09.001

Major Adverse Cardiovascular Events in Men with High-risk Localized or Metastatic Prostate Cancer Starting Long-term Hormone Therapy in the STAMPEDE Trial

Open DOI

Omar El-Taji, Peter Dutey-Magni, Mick Brown et al.

10 6 October 2026

DOI 10.1016/j.eururo.2026.09.003

Re: Targeted Prostate Cancer Screening in BRCA1 or BRCA2 Pathogenic Germline Variant Carriers Detects Clinically Relevant Disease: Five-year Results of the IMPACT Study

Open DOI

Francesco Greco